Latest robotic surgery
Reading File
Reading File
Reading File
“Latest” can mean new surgical systems, clinical evidence, or a specialty such as urology, gynecology, cardiac, or general surgery.
Asking for Preferences
Which aspect of robotic surgery should I cover?
“Latest” can mean new surgical systems, clinical evidence, or a specialty such as urology, gynecology, cardiac, or general surgery.Please specify what you want to know about robotic surgery:
- New technologies and surgical robots
- Latest clinical evidence and outcomes
- Updates in a specialty, such as urology, gynecology, cardiac, or general surgery
- Brief overall update
What are the newest robotic surgery systems in 2025–2026?
Reading File
Searching the Web
new surgical robotic systems launched 2025 2026 FDA cleared CMR Versius Medtronic Hugo Intuitive da Vinci 5 SS Innovations SSi Mantra
Searching PubMed
robotic surgery systems
Finding Sources
Searching the Web
site:cmrsurgical.com OR site:newsroom.cmr-surgical.com Versius Plus FDA clearance December 2025 cholecystectomy
Searching the Web
site:jnj.com Ottava surgical robot FDA submission 2026 clinical trial clearance OR site:intuitive.com da Vinci 5 launch 2025 2026 OR site:ssinnovations.com Mantra FDA 510k December 2025
Reading File
Reading File
Newest major robotic surgery systems, as of September 2026
| System | Company | What is new | Regulatory / market status |
|---|---|---|---|
| OTTAVA | Johnson & Johnson MedTech | A table-integrated, four-arm soft-tissue robot. The arms retract into the operating table, aiming to reduce operating-room footprint and facilitate multi-quadrant abdominal surgery. | The newest major U.S. entrant. FDA granted De Novo marketing authorization on July 22, 2026 for several general-surgery procedures, including gastric bypass, gastrectomy, cholecystectomy, sleeve gastrectomy, bowel resection, appendectomy, splenectomy, and adhesiolysis. J&J announcement |
| Hugo RAS | Medtronic | Modular system with separate mobile arm carts and an open surgeon console. It is designed to fit different operating-room configurations. | FDA-cleared in December 2025 for urologic surgery, with the U.S. rollout beginning in 2026. Medtronic clearance announcement |
| Versius Plus | CMR Surgical | Second-generation version of the compact, modular Versius platform. Its small independent arm units are intended to preserve familiar laparoscopic port placement and simplify operating-room integration. | FDA 510(k)-cleared in late 2025 for cholecystectomy, followed by U.S. commercialization. It had already been used extensively outside the United States. CMR Surgical update |
| SSi Mantra | SS Innovations | A modular, open-console, 3D-vision platform positioned as a lower-cost multi-specialty robot. It also has a strong focus on telesurgery capability. | Not yet FDA-cleared based on the latest information I found. The company filed a 510(k) in December 2025 for general, urologic, colorectal, gynecologic, and cardiac procedures. FDA filing report |
| da Vinci 5 | Intuitive Surgical | Not a 2025-2026 debut, but the newest generation of the dominant da Vinci platform. It adds markedly expanded computing capacity, force-feedback capability, and improved workflow/data features. | Commercially available since 2024 and still the benchmark system. In late 2025, Intuitive also expanded da Vinci SP indications to inguinal hernia repair, cholecystectomy, and appendectomy. 2025 robotics roundup |
What changed in 2025-2026
-
Real U.S. competition in soft-tissue robotics is finally emerging.
For many years, da Vinci dominated abdominal, pelvic, thoracic, and urologic robotic surgery. Hugo, Versius Plus, and now FDA-authorized OTTAVA create credible alternatives. -
Operating-room design is a major differentiator.
- OTTAVA: arms integrated into the table
- Hugo and Versius: modular, movable arm carts
- da Vinci: mature integrated platform with the broadest installed base
These designs affect room turnover, staffing, docking, patient positioning, and suitability for ambulatory surgery centers.
-
Robots remain surgeon-controlled rather than autonomous.
Most current systems are teleoperated master-slave systems: the surgeon controls instruments from a console. Limited automation, software guidance, data capture, and remote-operation features are expanding, but independently performing major operations is not routine clinical practice. Bailey and Love's Short Practice of Surgery, 28th ed., p. 187. -
FDA authorization is procedure-specific.
A system cleared for one operation is not automatically authorized for every surgical specialty. For example, Hugo's first U.S. clearance was for urology, whereas OTTAVA's initial authorization is for specified general-surgery procedures.
Bottom line
The two biggest developments are:
- OTTAVA, now the newest FDA-authorized major soft-tissue robotic platform in the United States.
- Hugo RAS and Versius Plus, which entered the U.S. market pathway in late 2025 and are expanding choice beyond da Vinci.
SSi Mantra is one of the most notable systems to watch, but its U.S. FDA clearance should not be assumed until formally announced.
This is a shared conversation. Sign in to Orris to start your own chat.